VTYX•globenewswire•
Ventyx Provides Clinical and Corporate Updates
Summary
SAN DIEGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with inflammation-mediated cardiovascular and neurodegenerative diseases, today announced that the Company added two leading experts to their advisory board and provided an update to its ongoing Phase 2 study of VTX2735 in patients with recurrent pericarditis (“RP”).
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on December 2, 2025 by globenewswire